Anika Therapeutics (ANIK) EBIT Margin (2010 - 2026)
Anika Therapeutics' (ANIK) quarterly EBIT Margin came in at 18.53% in Q1 2026, down 216.0% year-on-year from 15.98% in Q1 2025, and down 978.31% on a QoQ basis from 2.11% in Q4 2025.
Anika Therapeutics (ANIK) EBIT Margin (2010 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has 17 years of EBIT Margin data on file, last reported at 18.53% in Q1 2026.
- On a quarterly basis, EBIT Margin fell 216.0% year-over-year to 18.53% in Q1 2026; TTM through Mar 2026 was 10.54%, a 466.0% decrease from a year earlier, with the FY2025 full-year figure at 9.8%, down 554.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 18.53%, down from 2.11% in the prior quarter.
- Over the last five years, EBIT Margin for ANIK reached as high as 2.11% in Q4 2025 and fell as low as 852.09% in Q4 2023.
- Historically, EBIT Margin has averaged 94.67% across 5 years, with a median of 11.62% in 2025.
- Across the five-year window, EBIT Margin sank 56309 bps in 2022 and soared 84978 bps in 2024, its largest moves.
- Year by year, EBIT Margin stood at 588.55% in 2022, then slumped by 45 bps to 852.09% in 2023, then soared by 100 bps to 2.3% in 2024, then surged by 192 bps to 2.11% in 2025, then slumped by 978 bps to 18.53% in 2026.
- Per Business Quant data, the three most recent EBIT Margin figures were 18.53% in Q1 2026, 2.11% in Q4 2025, and 11.62% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Anika Therapeutics | 198.50 Mn | 131.71 Mn | 19.00 Mn | -18.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.53% |
| Dec 31, 2025 | 2.11% |
| Sep 30, 2025 | -11.62% |
| Jun 30, 2025 | -14.81% |
| Mar 31, 2025 | -16.37% |
| Dec 31, 2024 | -2.30% |
| Sep 30, 2024 | -0.27% |
| Jun 30, 2024 | -5.89% |
| Mar 31, 2024 | -8.63% |
| Dec 31, 2023 | -852.09% |
| Sep 30, 2023 | -18.51% |
| Jun 30, 2023 | -8.20% |
| Mar 31, 2023 | -33.10% |
| Dec 31, 2022 | -588.55% |
| Sep 30, 2022 | -14.40% |
| Jun 30, 2022 | -8.53% |
| Mar 31, 2022 | -9.69% |
| Dec 31, 2021 | -25.47% |
| Sep 30, 2021 | 3.29% |
| Jun 30, 2021 | 24.07% |